EXSCIENTIA
24.6.2021 13:02:14 CEST | Business Wire | Press release
EQRx , a company committed to developing and delivering important new medicines to patients at radically lower prices, and Exscientia , an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, today announced a strategic research and development collaboration agreement. The collaboration will leverage the AI capabilities of Exscientia to accelerate the discovery of multiple small molecule therapeutic drug candidates in therapeutic areas, including oncology and immunology, further expanding the breadth of EQRx’s pipeline of novel therapies.
This innovative collaboration is focused on creating significant improvements in the traditional drug discovery and development processes, by improving the probability of success through each company’s unique capabilities to accelerate the delivery of innovative new medicines—from discovery to commercialization.
Under the terms of the agreement, the strengths of both companies will be leveraged throughout the drug development process. Exscientia will lead the discovery phase through to Investigational New Drug application (IND) filing, while EQRx will be responsible for clinical development, regulatory and commercialization efforts. EQRx and Exscientia will equally share in the discovery, development and commercialization costs.
“Exscientia is a leader in AI-driven drug discovery, and of particular note, have now brought multiple AI-engineered drug candidates to clinical trials. We believe that our aligned focus on efficiency and quality sets a truly unique course to bring the next generation of innovative medicines to patients faster and at a fraction of the cost,” said Alexis Borisy, chairman and chief executive officer of EQRx. “This is a significant step in building EQRx’s robust, sustainable and industry-leading pipeline of important new medicines and substantially accelerates our early-stage research capabilities.”
“We are impatient for patients. EQRx and Exscientia are partners who are equally focused on re-engineering the way we create and distribute drugs for better outcomes for more patients. This exciting new collaboration brings together technologies through a new model that has the potential to truly disrupt how we think about efficiently creating innovative new medicines for all patients, ” said Andrew Hopkins, chief executive officer of Exscientia. “Together with the team at EQRx we look forward to building a successful partnership, to enable more patients to access better drugs, faster.”
About EQRx
EQRx is committed to catalyzing a market-based solution to one of society’s biggest healthcare challenges by developing important new medicines and offering them at lower prices. Through strategic partnerships with stakeholders from across the healthcare system and cutting-edge science and technology, the Company aims to provide high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. EQRx is a purpose-built disruptor at scale, remaking medicine to bend the cost curve in drug pricing. To learn more, visit www.eqrx.com
and follow us on social media: Twitter: @EQRxInc
, LinkedIn
, Instagram: @eqrxinc
.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI .
EQRx™ and Remaking Medicine™ are trademarks of EQRx, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005491/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Reports Topline Results From ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s9.6.2026 08:00:00 CEST | Press release
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced today that the Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s who have a pathogenic variant in the GBA1 gene (GBA-PD) did not meet its primary, nor the key secondary efficacy endpoints, meaning that BIA 28-6156 failed to slow the progression of GBA-PD versus placebo. BIA 28-6156 proved to be generally well tolerated in the study, with no unexpected safety concerns arising. While the study data provide valuable scientific information and contribute to a broader understanding of Parkinson’s biology, BIA 28-6156 did not demonstrate significant differentiation from placebo on the primary or key secondary endpoints measured. Based on the lack of demonstrated efficacy in this study, Bial has made the decision to discontinue further development of BIA 28-6156 for this indication. “We are disappointed with the outcome of the Phase 2b ACTIVATE study, as th
Avanzanite Expands into Spain and Appoints María Baquerizo as Country Manager9.6.2026 07:30:00 CEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into Spain and the appointment of María Baquerizo López-Quectuy as Spain Country Manager. This follows a €32 million Series A investment by MVM Partners announced in November 2025 and the recent entry to France. Avanzanite’s continues to build its integrated European platform designed to accelerate access to innovative therapies for people living with rare diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608541655/en/ María Baquerizo López-Quectuy, Country Manager, Avanzanite Spain “Spain is an essential part of Avanzanite’s European vision,” said Adam Plich, Co-Founder and CEO, Avanzanite Bioscience. “The country combines scientific excellence, a sophisticated healthcare ecosystem and a large community of patients living with rare diseases who continue to
Cursor Announces EMEA Office and Team Expansion to Meet Regional Demand9.6.2026 07:00:00 CEST | Press release
London headquarters will open this summer and grow to approximately 200 employees by year-end as EMEA becomes Cursor's fastest-growing region Cursor, the leading multi-model AI coding platform, today announced the establishment of dedicated teams to serve the EMEA region. The expansion responds to regional momentum, with EMEA revenue tripling quarter over quarter this year. The Cursor EMEA team will support a rapidly expanding customer base that includes British Airways, BP, Deliveroo, Nokia, Sanofi and many other leading enterprises across the region. Cursor expects to grow its EMEA headcount to approximately 200 employees by the end of the year, hiring across go-to-market, engineering, customer success and operations. “We’re incredibly excited to officially launch Cursor across EMEA and deepen our commitment to customers and partners throughout Europe. As the leading AI coding company, our goal is simple: be closer to the teams building the future and help enterprises accelerate thei
Signaloid to Preview New ASIC and Demo of Its UxHw® Technology at Bosch Connected World9.6.2026 07:00:00 CEST | Press release
British AI hardware company Signaloid will preview its recently-taped-out ASIC for physical AI at Bosch Connected World, from 10th–11th June 2026, in Berlin.The ASIC is complementary to Signaloid’s edge hardware modules which are already achieving over 37-fold speedup for algorithms used in physical AI and robotics. British computing technology company Signaloid will preview its C0-ASIC for physical AI this week at Bosch Connected World, taking place from 10th-11th June, in Berlin. Designed for robotics, industrial automation, and probabilistic AI workloads, the ASIC is projected to deliver up to 1000× better performance-per-Watt than existing state-of-the-art approaches. Signaloid’s distribution-extended compute hardware (UxHw®) is already available for use in physical AI/robotics as a family of hardware modules, as well as via a virtualization- and binary-translation-based solution. UxHw enables autonomous mobile robots (AMRs) to improve their navigation algorithms for safer and fast
Hitachi and Google Cloud Expand Strategic Alliance to Accelerate Real-world Deployment of Physical AI Through FDE and Advanced Cybersecurity Solutions9.6.2026 02:20:00 CEST | Press release
Hitachi and Google Cloud will bolster FDE capabilities to accelerate physical AI globally by combining Hitachi’s co-creation approach and digital engineering capabilities cultivated through Lumada with Google Cloud’s advanced AI. Through the development of these FDE capabilities, Hitachi and Google Cloud will enhance HMAX using Gemini Enterprise, helping solve frontline worker challenges through autonomous operations in complex environments. By scaling FDE knowledge, Hitachi will deliver value to a wider range of customers. Expanding the collaboration, Hitachi and Google Cloud will enable customers to bolster their cyber defense capabilities against AI-driven cyber threats. Hitachi, Ltd. (TSE:6501, "Hitachi") today announced the expansion of its strategic alliance*1 with Google Cloud to support customers by accelerating the real-world deployment of physical AI and cybersecurity solutions to protect against AI generated threats. Garnering increasing attention, physical AI is a technolog
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom